BERGEN, Norway, Aug. 30, 2018 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), announces that Richard
Godfrey, CEO of BerGenBio, is scheduled to present an
overview of the Company's business and ongoing phase II clinical
development programme with its first-in-class selective AXL
inhibitor bemcentinib at the 20th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC, on September 5th
2018 at 9:35 AM (Eastern
Time).
The presentation will be webcast live. To access presentation
slides and webcast, please
visit www.bergenbio.com/investors/presentations/. The
webcast replay will remain available for 90 days following the live
presentation.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for advanced and aggressive
cancers.
The company's proprietary lead candidate, bemcentinib, is a
potentially first-in-class selective AXL inhibitor in a broad phase
II clinical development programme. Ongoing clinical trials are
investigating bemcentinib in multiple solid and haematological
tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy),
and as a single agent.
In parallel, BerGenBio is developing companion diagnostics test
to identify patient populations most likely to benefit from
bemcentinib; this is expected to facilitate more efficient
registration trials and support a precision medicine-based
commercialisation strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). www.bergenbio.com
About AXL
AXL kinase is cell membrane receptor and an essential mediator
of the biological mechanisms that drive aggressive and
life-threatening diseases. In cancer, AXL drives tumour survival,
treatment resistance and spread, as well as suppressing the body's
immune response to tumours. AXL expression has been established as
a negative prognostic factor in many cancers. AXL inhibitors,
therefore, have potential value at the centre of cancer combination
therapy, addressing significant unmet medical needs and multiple
high-value market opportunities.
Forward-Looking Statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47-917-86-304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513
Media Relations in Norway
Jan Petter Stiff, Crux
Advisers
stiff@crux.no
+47-995-13-891
International Media Relations
David Dible
Mark Swallow
Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44-207-638-9571
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/bergenbio-asa/r/bergenbio-to-present-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-,c2604131
View original
content:http://www.prnewswire.com/news-releases/bergenbio-to-present-at-the-20th-annual-global-investment-conference-in-new-york-city-september-4-6-2018-300704708.html
SOURCE BerGenBio ASA